anonymous
Guest
anonymous
Guest
Dog !?! You must be jokin that puppy is magic !!
Remember irinotecan is a generic drug - patients do not "Have" to get the liposome
After 12 months, 26 percent of patients treated with the Onivyde combination remained alive compared with 16 percent with 5-FU plus leucovorin alone. At approximately 20 months, survival was similar between the two groups.
See if you skip irinotecan completely Onivyde is proven to be better than nothing... well at least temporarily
Fortunately Onivyde has never been tested versus good old fashioned irinotecan alone - then the "mythic liposome" BS might be disproved
Remember irinotecan is a generic drug - patients do not "Have" to get the liposome
After 12 months, 26 percent of patients treated with the Onivyde combination remained alive compared with 16 percent with 5-FU plus leucovorin alone. At approximately 20 months, survival was similar between the two groups.
See if you skip irinotecan completely Onivyde is proven to be better than nothing... well at least temporarily
Fortunately Onivyde has never been tested versus good old fashioned irinotecan alone - then the "mythic liposome" BS might be disproved
anonymous
Guest
anonymous
Guest
"Magic?" I don't think so:Dog !?! You must be jokin that puppy is magic !!
Remember irinotecan is a generic drug - patients do not "Have" to get the liposome
After 12 months, 26 percent of patients treated with the Onivyde combination remained alive compared with 16 percent with 5-FU plus leucovorin alone. At approximately 20 months, survival was similar between the two groups.
See if you skip irinotecan completely Onivyde is proven to be better than nothing... well at least temporarily
Fortunately Onivyde has never been tested versus good old fashioned irinotecan alone - then the "mythic liposome" BS might be disproved
Onivyde was originally approved in late 2015 for metastatic pancreatic cancer, but its sales have underwhelmed, chalking up just $14.5m in the third quarter. With its chunky offer, Ipsen, and its new Chief Executive David Meek, must believe that the French group can make a better fist of selling the product.
But given Onivyde’s less-than-impressive data in improving overall survival, this is going to be hard, even for a new and enthusiastic management team. According to EvaluatePharma consensus of banks covering Merrimack, Onivyde is forecast to have sales of $619m by 2022, though Oddo analysts, covering Ipsen, put the drug's peak sales at a mere €200m ($211m).
anonymous
Guest
anonymous
Guest
it will take more than a fist to sell reformulated generic drugs. with tiny sales and shitty data - Meeks will inherit the earth
anonymous
Guest
anonymous
Guest
anonymous
Guest
onivyde is third line....and used rarely if at all.......by the time a MPAC patient reaches third line, they are back on Gem.....wasn't there a pipeline attached to that deal...or did Ipsen only buy the one drug.....
anonymous
Guest
anonymous
Guest
onivyde is third line....and used rarely if at all.......by the time a MPAC patient reaches third line, they are back on Gem.....wasn't there a pipeline attached to that deal...or did Ipsen only buy the one drug.....
I thought Onivyde was second-line, no?
anonymous
Guest
anonymous
Guest
onivyde is third line....and used rarely if at all.......by the time a MPAC patient reaches third line, they are back on Gem.....wasn't there a pipeline attached to that deal...or did Ipsen only buy the one drug.....
The pipeline is why the deal happened
anonymous
Guest
anonymous
Guest
I thought Onivyde was second-line, no?
No 3rdL
anonymous
Guest
anonymous
Guest
onivyde is pushed to 3rdL in sequencing......in real life...
MM-398 (Onivyde) is irinotecan, approximately 80,000 molecules, encapsulated in a nanoparticle, liposome drug delivery system. In preclinical studies, this formulation improves pharmacokinetics and tumor biodistribution of both irinotecan and its active metabolite, SN-38, compared with free irinotecan. This leads to increased efficacy as observed in an orthotopic PC mouse model with less exposure to non-target organs and associated toxicities. MM398 was studied in a randomized phase III trial (NAPOLI-1) in 417 gemcitabine-refractory metastatic cancer patients (11). This 2nd line trial randomized patients to either MM-398 alone, MM-398 + 5-FU/LV, or the control arm of 5-FU/LV, with OS as the primary endpoint. Patients on the MM-398 + 5-FU/LV arms achieved a median OS benefit of 6.1 vs. 4.2 months for the 5-FU/LV control arm (HR 0.68, P=0.014). There was no statistical benefit for the single agent MM-398 arm compared to control. MM-398 is approved by the FDA for treatment of patients with advanced PC who was previously treated with gemcitabine-based chemotherapy.
With MM-398 now available, sequencing of treatments for PC can be considered. If patients receive a gemcitabine-based regimen in the first-line setting, it is practical to use MM-398 as 2nd line treatment. This is especially true for patients receiving nab-P or oxaliplatin in whom neuropathy and thrombocytopenia are common adverse events leading to treatment discontinuation. The MM398/5-FU/LV regimen is not associated with these specific side effects. If patients receive upfront FOLFIRINOX, a gemcitabine-based combination such as gemcitabine/nab-P can be considered but this places MM-398 to a later line of treatment and fewer patients would be eligible for treatment with the agent. Whichever approach is favored, the need to strategize which regimen to use in the first-line to facilitate treatment in the second line is a new and welcomed consideration in the treatment of advanced PC.
MM-398 (Onivyde) is irinotecan, approximately 80,000 molecules, encapsulated in a nanoparticle, liposome drug delivery system. In preclinical studies, this formulation improves pharmacokinetics and tumor biodistribution of both irinotecan and its active metabolite, SN-38, compared with free irinotecan. This leads to increased efficacy as observed in an orthotopic PC mouse model with less exposure to non-target organs and associated toxicities. MM398 was studied in a randomized phase III trial (NAPOLI-1) in 417 gemcitabine-refractory metastatic cancer patients (11). This 2nd line trial randomized patients to either MM-398 alone, MM-398 + 5-FU/LV, or the control arm of 5-FU/LV, with OS as the primary endpoint. Patients on the MM-398 + 5-FU/LV arms achieved a median OS benefit of 6.1 vs. 4.2 months for the 5-FU/LV control arm (HR 0.68, P=0.014). There was no statistical benefit for the single agent MM-398 arm compared to control. MM-398 is approved by the FDA for treatment of patients with advanced PC who was previously treated with gemcitabine-based chemotherapy.
With MM-398 now available, sequencing of treatments for PC can be considered. If patients receive a gemcitabine-based regimen in the first-line setting, it is practical to use MM-398 as 2nd line treatment. This is especially true for patients receiving nab-P or oxaliplatin in whom neuropathy and thrombocytopenia are common adverse events leading to treatment discontinuation. The MM398/5-FU/LV regimen is not associated with these specific side effects. If patients receive upfront FOLFIRINOX, a gemcitabine-based combination such as gemcitabine/nab-P can be considered but this places MM-398 to a later line of treatment and fewer patients would be eligible for treatment with the agent. Whichever approach is favored, the need to strategize which regimen to use in the first-line to facilitate treatment in the second line is a new and welcomed consideration in the treatment of advanced PC.
anonymous
Guest
anonymous
Guest
onivyde is pushed to 3rdL in sequencing......in real life...
MM-398 (Onivyde) is irinotecan, approximately 80,000 molecules, encapsulated in a nanoparticle, liposome drug delivery system. In preclinical studies, this formulation improves pharmacokinetics and tumor biodistribution of both irinotecan and its active metabolite, SN-38, compared with free irinotecan. This leads to increased efficacy as observed in an orthotopic PC mouse model with less exposure to non-target organs and associated toxicities. MM398 was studied in a randomized phase III trial (NAPOLI-1) in 417 gemcitabine-refractory metastatic cancer patients (11). This 2nd line trial randomized patients to either MM-398 alone, MM-398 + 5-FU/LV, or the control arm of 5-FU/LV, with OS as the primary endpoint. Patients on the MM-398 + 5-FU/LV arms achieved a median OS benefit of 6.1 vs. 4.2 months for the 5-FU/LV control arm (HR 0.68, P=0.014). There was no statistical benefit for the single agent MM-398 arm compared to control. MM-398 is approved by the FDA for treatment of patients with advanced PC who was previously treated with gemcitabine-based chemotherapy.
With MM-398 now available, sequencing of treatments for PC can be considered. If patients receive a gemcitabine-based regimen in the first-line setting, it is practical to use MM-398 as 2nd line treatment. This is especially true for patients receiving nab-P or oxaliplatin in whom neuropathy and thrombocytopenia are common adverse events leading to treatment discontinuation. The MM398/5-FU/LV regimen is not associated with these specific side effects. If patients receive upfront FOLFIRINOX, a gemcitabine-based combination such as gemcitabine/nab-P can be considered but this places MM-398 to a later line of treatment and fewer patients would be eligible for treatment with the agent. Whichever approach is favored, the need to strategize which regimen to use in the first-line to facilitate treatment in the second line is a new and welcomed consideration in the treatment of advanced PC.
Thanks for the explanation.
The prospects aren't exactly promising for this one then, I take it?
anonymous
Guest
anonymous
Guest
Thanks for the explanation.
The prospects aren't exactly promising for this one then, I take it?
Current indication not so much. The future looks very promising.
anonymous
Guest
anonymous
Guest
Would this be a good opportunity to break into oncology and pull 5 or so years of experience as a stepping stone?
Is management willing to team up with their reps and win?
Are the drugs part of the pathway used and are goals attainable?
Is there really an $8k per quarter increase in bonus after launch of onivyde?
What is the vacation time I keep hearing about?
What is the worst part of working for Ipsen?
What is your favorite thing about Ipsen?
Anything else we should know?
I currently work for a good company but so much bureaucracy and big pharma mindset/bs that enough is enough if this is worth it.
I just wanna sell and get paid. I have worn many hats and been recognized as someone who has a history of success across my career. Can't imagine this being a bad opportunity.
Is management willing to team up with their reps and win?
Are the drugs part of the pathway used and are goals attainable?
Is there really an $8k per quarter increase in bonus after launch of onivyde?
What is the vacation time I keep hearing about?
What is the worst part of working for Ipsen?
What is your favorite thing about Ipsen?
Anything else we should know?
I currently work for a good company but so much bureaucracy and big pharma mindset/bs that enough is enough if this is worth it.
I just wanna sell and get paid. I have worn many hats and been recognized as someone who has a history of success across my career. Can't imagine this being a bad opportunity.
anonymous
Guest
anonymous
Guest
Would this be a good opportunity to break into oncology and pull 5 or so years of experience as a stepping stone?
Is management willing to team up with their reps and win?
Are the drugs part of the pathway used and are goals attainable?
Is there really an $8k per quarter increase in bonus after launch of onivyde?
What is the vacation time I keep hearing about?
What is the worst part of working for Ipsen?
What is your favorite thing about Ipsen?
Anything else we should know?
I currently work for a good company but so much bureaucracy and big pharma mindset/bs that enough is enough if this is worth it.
I just wanna sell and get paid. I have worn many hats and been recognized as someone who has a history of success across my career. Can't imagine this being a bad opportunity.
Too many questions, but
It's currently a good job but it's going to be rough for a few quarters. People are still doing great and making money.
This is a company in constant transition and removing in the right direction. Look at the stock price.